|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:Genentech
|
|
gptkbp:activities
|
VEGF inhibitor
|
|
gptkbp:administrative_division
|
eye
|
|
gptkbp:appointed_by
|
injection
|
|
gptkbp:approves
|
gptkb:2006
|
|
gptkbp:class
|
gptkb:monoclonal_antibody
|
|
gptkbp:clinical_trial
|
gptkb:ANCHOR_trial
gptkb:CATT_trial
gptkb:IVAN_trial
gptkb:MARINA_trial
gptkb:myopic_choroidal_neovascularization
Phase III
diabetic retinopathy
neovascular (wet) age-related macular degeneration
|
|
gptkbp:competitors
|
gptkb:Avastin
gptkb:Eylea
gptkb:Beovu
gptkb:Ozurdex
|
|
gptkbp:contraindication
|
active ocular infection
hypersensitivity to ranibizumab
uncontrolled systemic disease
|
|
gptkbp:dosage_form
|
gptkb:software_framework
|
|
gptkbp:effective_date
|
FDA approved
|
|
gptkbp:formulation
|
sterile solution
|
|
gptkbp:frequency
|
monthly
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lucentis
|
|
gptkbp:ingredients
|
gptkb:ranibizumab
|
|
gptkbp:invention
|
gptkb:2020
|
|
gptkbp:is_available_in
|
vials
|
|
gptkbp:is_used_for
|
treatment of age-related macular degeneration
treatment of diabetic macular edema
treatment of retinal vein occlusion
|
|
gptkbp:manager
|
intravitreal injection
|
|
gptkbp:manufacturer
|
gptkb:Genentech
|
|
gptkbp:marketed_as
|
gptkb:brand
|
|
gptkbp:packaging
|
single-use vial
|
|
gptkbp:population
|
adults
elderly
|
|
gptkbp:price
|
high
|
|
gptkbp:provides_information_on
|
gptkb:American_Academy_of_Ophthalmology
gptkb:National_Institute_for_Health_and_Care_Excellence
|
|
gptkbp:research_focus
|
combination therapy
cost-effectiveness
safety profile
long-term efficacy
|
|
gptkbp:safety_features
|
risk of thromboembolic events
risk of endophthalmitis
risk of retinal detachment
|
|
gptkbp:side_effect
|
conjunctival hemorrhage
eye pain
intraocular pressure increase
vitreous floaters
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:traded_on
|
gptkb:Lucentis
|